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Introduction
This 12-month audit (conducted between 1st July 2011 to
30th June 2012) was designed following a retrospective
audit in a specialist neuromuscular centre (UK) using
DBS testing to identify late-onset Pompe disease. The
objective was to screen all patients with an unknown
diagnosis presenting with a limb girdle pattern of muscle
weakness +/- respiratory symptoms +/- scoliosis +/- rigid
spine that were seen in the clinic, including new referrals
and follow-up patients. Our goal is to improve the detec-
tion rate of Pompe disease and to initiate early treatment
in clinical practice. To that end, this audit has been
extended through June 2013.
Results
Out of 102 patients, six positive tests were obtained on
DBS (5.9%), one of which was a false positive in a patient
aged 40 years (CK>1000, symptoms from adulthood,
resp. problems; ventilated at night). Five positive cases
were subsequently confirmed (4.9% - plus one additional
case identified as a family member). These cases will be
reported in detail. If not in the audit, these patients
would not have been diagnosed with Pompe disease on
the basis of their symptoms.
Conclusion
Pompe disease is a progressive, debilitating and often
fatal neuromuscular disorder that presents with a conti-
nuum of clinical phenotypes that vary with regards to
organ involvement, age of onset, disease severity and
rate of progression. Early diagnosis is key to implement-
ing early disease modifying treatment. Whilst all these
patients detected have some of the features that have
been documented in Pompe disease, it is vital that clini-
cians are alerted to the subtle presentation that late
onset Pompe can have. DBS is a rapid test that improves
the time to diagnosis, and hence, time to treatment, as
suggested in the International Consensus meeting [1].
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